

Oncology Medical Home Progress and Status

Bruce Gould, MD Northwest Georgia Oncology OMH Steering Committee Chair



Drivers Towards Quality and Value

- Accountable Care Organizations
 - Cost savings
 - · Quality measures
- Hospital Compare
 - Hospitals measured, and paid, on patient satisfaction and outcomes
- Physician Compare
- Physician payment "value-based modifier"
- Quality & Resource Use Report
 - Pilot in Iowa, Kansas, Missouri, Mississippi & Nebraska
- Cancer specific projects



Accountable Care Organizations

- Big picture
 - · Primary care driven
 - Specialists cannot take the lead in forming an ACO but can participate in it
 - Clearly is driven by primary care and large integrated systems
 - Some easing of anti-trust provisions designed to hinder coordination of care in the first place
 - Share in the savings if quality metrics (33) are met
 - Not cancer care friendly
 - Take on more risk, more potential return
- "Cancer" mentioned only 15 times in 694 pages!
- "Cancer care" not mentioned at all




3


Hospital Compare



Physician Compare




Physician Value Based Modifier



Oncology Medical Home

Source: 08/01/12 CMS Presentation on Value Based Modifier

MD Quality & Use Resource Report



Implications for Oncology

- Medicare and private payers are moving towards payments based on performance
 - Outcomes
 - Value
 - Emphasis on reducing costs!
 - Quality
 - Patient Satisfaction
- Moving away from utilization (only) based systems
- All want comprehensive solutions



Oncology and the Medical Home Model

- Most oncology practices already function to 80-85% of the medical home model
 - · Center of the patient's world
 - Care coordination
- What's typically missing?
 - · Going the "next step" in care coordination
 - IT support focused on the patient
 - Measurement
 - Quality
 - Value
 - Patient satisfaction
 - Payment
 - Recognition
 - Reward



9

What is the COA OMH Gameplan?

- Create general consensus and unity among stakeholders about what each wants from cancer care
 - Patients
 - Payers
 - Providers
- Agree on <u>quality</u> and <u>value</u>
 - Measures
 - With benchmarking
 - Patient satisfaction
 - With benchmarking
- Create a template for viable payment
 - Private payers
 - Medicare
- Help practices implement
 - Process change
 - Payer contracting



COA OMH Implementation Efforts

COA Board

- · Set overall strategy & direction
- Empower the process

Steering Committee

- Provide guidance & consensus
- · Identify stakeholder perspectives
- Develop quality & value measures
- Oversee overall implementation

Implementation Team

- Identify practice needs
- · Establish an implementation roadmap
- · Create information sharing among practices





11

OMH Steering Committee

Oncologists	Bruce Gould, MD (GA) Chair Northwest Georgia Oncology	Payers	Lee Newcomer, MD United Insurance Group
	Patrick Cobb, MD (MT) Frontier Cancer Center		Ira Klein, MD Aetna Insurance Company
	Roy Beveridge, MD McKesson/US Oncology		Michael Fine, MD Healthnet
	John Sprandio, MD (PA) Consultants in Medical Oncology		Dexter Shurney, MD Cummins Inc.
Administrators	Scott Parker (GA) Northwest Georgia Oncology		John Fox, MD Priority Health
	Robert Baird (OH) Dayton Physician Network	Patient	Kathy Smith, NP (CA) Cancer Care Associates
Cancer Care Advocates	National Patient Advocacy Foundation	Nurse	Marsha Devita, NPA (NY) Hem Onc Assoc of CNY
	Robert Hauser, Pharm D ASCO	Pharmacist	Karen Kellogg, Pharm D (UT) Utah Cancer Specialists
	Trish Goldsmith NCCN	Business Partner	Dave Leverett Amerisource Bergen



OMH Implementation Team

- Carol Murtaugh RN OCN, NE (Chair)
- Kent Butcher, OK
- Kristy McGowan, UT
- Maryann Roefaro, NY
- Donna Krueger, IL
- John Hennessey, KS
- Alice Canterbury, SC
- Marissa Rivera, CA



13

Stakeholder Needs

Patients	Payers	Providers
Best Possible Outcome	Best Possible Clinical Outcomes	Best Outcome for Patient
Docs with the 3 A's (Able, affable, accessible)	Member Satisfaction / Experience	Satisfied patients and family
Least Out Of Pocket Expense	Control Total Costs / Variability	Fairest Reimbursement to Provide Quality Patient Care
Education and Engagement of the Patient in the Care Plan	Productivity / Survivorship	Compensated for Cognitive Services Including Treatment Planning, End of Life Care and Survivorship.
Best Quality of Life Oncology Medical Home	Meaningful Proof of Quality / Value	Less Administrative Burdens


Quality, Value, Outcomes Measures

<i>C</i> // /
atient Care Measures
of cancer patients that received a treatment plan prior to the administration of chemotherapy.
of cancer patients with documented clinical or pathologic staging prior to initiation of first course of treatment.
of chemotherapy treatments that have adhered to NCCN guidelines or pathways.
ntiemetic drugs given appropriately with highly emetogenic chemotherapy treatments.
of cancer patients undergoing treatment with a chemotherapy regimen with a 20% or more risk of developing neutropenia and also received GCSF/white cell growth factor.
tesource Utilization
of emergency room visits per chemotherapy patient per year.
of hospital admissions per chemotherapy patient per year.
urvivorship
of cancer patients that received a survivorship plan within X days after the completion of chemotherapy.
of chemotherapy patients that received psycho/social screening and received measurable interventions as a result of the psycho/social screening.
urvival rates of stage I through IV breast cancer patients.
urvival rates of stage I through IV colorectal cancer patients.
urvival rates of stage I through IV NSC lung cancer patients.
nd of Life
of patients that have Stage IV disease that have end-of-life care discussions documented.
verage # of days under hospice care (home or inpatient) at time of death.
of patient deaths where the patient died in an acute care setting.
measurement of chemotherapy given near end of life.



15

Oncology Medical Home Summary







How to get there from here

Carol Murtaugh Hematology & Oncology Consultants, PC OMH Implementation Committee Chair



Challenges

- Limited time
- Limited human resources
- Limited financial resources
- Conflicting priorities
- Increased regulations
- Decreased payments





OMH - Goals and Focus


- Stakeholder led for stakeholders
- Agnostic
- Minimal administrative burden
 - Possibly ease the burden
- Minimal financial burden
 - Goal of enhancing financial position
- FREE Wherever possible
 - Or discounted value added resources
- All intended to ease assist, promote and encourage



19

OMH - Goals and Focus

- Assist with the journey
- One step at a time







Self - Assessment

Bo Gamble Community Oncology Alliance



How to get there here ...

- Many solutions
 - Simple to complex
 - · Free to nominal fees to professional consulting
- As much about education as moving forward
- Involves
 - Educating team
 - Process improvement
 - · Benchmarking success and improvement
 - Incorporating payment reform





OMH Website - Resources and Benchmarking

Carol Murtaugh Hematology & Oncology Consultants, PC OMH Implementation Committee Chair



What:

A Website to Promote...

- Quality and value in cancer care
- Delivery of the right care, at the right time and at the right place
- All good things in cancer care



Oncology Medical Home

What:

A Website to Assist...

- Providers
 - OMH information and tips
 - Patient management resources
 - Patient assistance resources
 - Practice management resources
 - · Patient satisfaction tools and benchmarking
- Patients
 - OMH Information
- Payers
 - OMH information
- Secure portal to view authorized benchmarks
 Oncology Medical Home

2.5

www.MedicalHomeOncology.org



What:

A Website to provide

- Infrastructure to:
 - · Submit blinded patient data
 - Specific to 16 OMH quality and value measures
 - In the form of registry
 - That could be used for ratio calculations and benchmarking
 - In a secure, and by invitation only, environment
 - · And promoting continuous improvement



27



ONCOLOGY MEDICAL HOME

Payment Reform

Bo Gamble Community Oncology Alliance



Current Initiatives

- Pennsylvania John Sprandio
 - · The oncology medical home pioneer
 - Measuring quality and value (costs)
 - · Working with private payers on contracting/reimbursement
 - Incentive based reimbursement
- Michigan
 - · PriorityHealth with multiple practices
 - Base pay, case management, incentives on positive outcomes.
- National Barbara McAneny M.D.
 - CMMI award
 - · Value focus with patient satisfaction



29

Payment Reform Task Force

- Single proposal for Medicare
- Go beyond
 - · Pay for Reporting
 - · Pay for Guideline Adherence
 - · Pay for Episode of Care
- Provide appropriate, realistic reimbursement
- Recognize and reward quality, value, and positive outcomes.
- Do not prioritize cost savings over best patient treatment
- Incent patient engagement and feedback
- Do not further destabilize the unstable Medicare pricing system leading to drug shortages





Medicare Payment Reform for Oncology

Ensuring the Delivery of Quality & Value-Based Cancer Care



Drugs at ASP + 6%
E&M
Onc/Hem Services
Quality/Value
Performance

Drugs at ASP + 6% E&M Onc/Hem Services Shared Savings

(Bundling, Episode of Care, etc) Shared Savings

Implement within 5 years Practice assumes risk component, with possibly

varying degrees bundling, episode of care,

etc. In return, practice receives higher % of shared

Shared savings benchmarked against

utilization and

radiation pathways

appropriate comparison

group. Savings focused on Measures* relating to ER

hospitalizations, as well as drug, imaging, and

savings

Implement within 1 year

Current fee-for-service (FFS) payment structure for drugs and services (E&M and Oncology/Hematology [Onc/Hem] specific codes).

Compliance with
Measures* reporting
qualifies practice to receive
Medicare Economic Index
(MEI) increase.

Additional payment tied to Measures reporting & Oncology Patient Satisfaction (OPS) reporting — 0% to 2% Quality/Value Adjustment (QVA) based on formula.

*Measures are Stage I (see following pages) and full OPS reporting. Implement within 2 years

Current FFS payment structure for drugs and services (E&M and Onc/Hem specific codes).

Compliance with Measures* reporting qualifies practice to receive MEI increase.

Additional payment or decrease tied to relative Measures performance & OPS performance — -2% to 5% QVA based on formula.

*Measures are Stage I & II (see following pages) and full OPS reporting. Implement within 3 years

Current FFS payment structure for drugs and services (E&M and Onc/Hem specific codes).

50/50 shared savings benchmarked against appropriate comparison group. Savings focused on Measures* relating to ER utilization and hospitalizations, and drug pathways. Possible inclusion of imaging and radiation pathways.

Participation in shared savings qualifies practice to receive MEI increase.

*Measures are Stage I & II (see following pages) and full OPS reporting. Participation in shared savings qualifies practice to receive MEI increase.

Measures are Stage I, II & III (III if feasible; see following pages)) and full OPS reporting.

GENERAL NOTE

Assumes suspension of the sustainable growth rate (SGR) for oncology/hematology.

In Summary

- Stakeholder led, defined and implemented
 - Scalable to ALL cancer care providers
 - Minimal administrative burden
 - Minimal financial burden
- Education
- Process
- Measurement
- Benchmarking
- Payment Reform
- Win for Patients, Providers, ALL Payers
 - · Higher quality
 - Higher value





OMH Next Steps

- Continue to enroll practices/centers
 - OMH Implementation Team here to assist
- Continue to identify resources that can assist
- Finalize and promote quality data registry
- Benchmark 16 OMH quality and value measures
- Promote automated submission of quality data
- Identity a "recognition" entity
- Continue to promote and implement reward based payment reform



33

Thank You!

Bruce Gould M.D.

OMH Steering Committee Chair

BJG83@NGOC.com

Carol Murtaugh

OMH Implementation Committee Chair

CMurtaugh@hocdocs.com

Bo Gamble Community Oncology Alliance Bgamble@COAcancer.org

